Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia.

Journal of atherosclerosis and thrombosis - 1 Jul 2016

Kolovou Genovefa D, Kolovou Vana, Papadopoulou Anna, Watts Gerald F

Abstract excerpt

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder, which leads to premature cardiovascular diseases. Microsomal triglyceride transport protein (MTP) inhibitors, such as lomitapide, offer a new therapeutic approach for treating these patients. We evaluated the lipid lowering (LL) efficacy of lomitapide according to several gene variants in MTP. Four clinically and/or molecularly defined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carrier Proteins

Share to Genetic Variation

Share to Homozygote

Share to Hyperlipoproteinemia Type II

Share to Polymerase Chain Reaction

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 27170061
DOI: 10.5551/jat.34777
PMCID: PMC7399272

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia.PMID 27170061Read ↗

MTTP gene variants and lomitapide response in a cohort of patients with homozygous familial hypercholesterolemiaSemantic proximity Read ↗

Lomitapide for the management of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Lomitapide for the treatment of hypercholesterolemia.Semantic proximity Read ↗

Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.Semantic proximity Read ↗

Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.Semantic proximity Read ↗

Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia.Semantic proximity Read ↗

Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.Semantic proximity Read ↗

Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.Semantic proximity Read ↗

Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.